What We Are Watching
Pharma · Biotech · Logistics
Cold Chain Infrastructure Was Designed for the Last Drug Portfolio. The Next One Requires Something Different.
Cell and gene therapies require cryogenic temperatures that most existing cold chain infrastructure cannot support at scale. The pharmaceutical cold storage market is projected to double by 2035. The investment response has been incremental. Multiple industries are adding cold chain demand simultaneously. The gap is structural.
4/1/2026
What We Are Watching is Vaxa's signal intelligence column. We identify markets, technologies, and structural shifts already in motion but may not yet reached the corporate strategy conversation.
highlights
01
The pharmaceutical cold chain was designed for a previous drug portfolio — biologics and cell therapies are structurally more demanding
02
Cell and gene therapies require cryogenic temperatures that most existing cold chain infrastructure cannot support at scale
03
The cold storage market is projected to double by 2035 — investment has been incremental, not transformational
04
Multiple industries are adding cold chain demand simultaneously — pharma, food, agri-biotech, specialty chemicals
05
The gap between announced investment and operational capacity is measured in years, not quarters
Signal
Cold chain infrastructure is not a new problem. Refrigerated storage and temperature-controlled logistics have existed for decades — built initially around food, extended to conventional pharmaceuticals, and expanded again during the COVID vaccine rollout. Investment continues. Announcements are made. Capacity is added.
What is not keeping pace is the nature of what is now moving through the system. The drug pipeline has shifted in ways that make the existing cold chain framework — designed around a previous generation of therapies — increasingly inadequate for what is coming next.
The pharmaceutical cold storage market is projected to double by 2035. The investment response has been incremental. Those two facts do not resolve neatly.
Pattern
The mix of newly approved drugs has been quietly tilting toward biologics for years. Biologics now represent approximately a third of all new FDA drug approvals. More than 85% of biologics require temperature-controlled manufacturing, storage, and distribution.
Cell and gene therapies require cryogenic temperatures, often below −130°C. Any temperature deviation does not degrade the product — it destroys it. The therapy is a living drug. There is no salvage.
A biologic that arrives two degrees warm is not a biologic anymore. It is a loss, with no salvage value and no second chance.
Mechanism
The cold chain pressure is not confined to pharmaceuticals. In food and agriculture, the growth of plant-based proteins and rapid e-grocery delivery has compressed temperature-controlled last-mile expectations. Agri-biotech is an emerging pressure point — biological pesticides, microbial soil inoculants, and live agricultural cultures all require cold storage across supply chains that are often rural and infrastructure-constrained.
Every industry adding cold chain demand right now is competing for the same limited pool of qualified capacity, vehicles, and trained workforce.
Implication
The challenge is not that no one is investing in cold chain capacity. The tension is that investment decisions are calibrated to current demand signals, while the demand curve driven by the drug pipeline is non-linear and accelerating.
Cold storage facilities take years to permit, build, validate, and certify. The lag between the decision to invest and the availability of operational capacity is measured in years — not quarters.
A facility under construction is not capacity. It is a promise with a completion date attached.
Question
The companies most exposed are the ones assuming that announced cold chain investment translates into available capacity on their timeline. Given how long these facilities take to permit, build, and certify, that assumption is the actual risk — not the underlying demand, which is well documented and accelerating.
The demand for cold chain capacity is not the uncertain part of this story. The supply timeline is.
The question to ask.
Was your cold chain coverage designed for the product complexity you are moving toward — or the complexity that existed when the infrastructure was built?